ProKidney Corp. (PROK)
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
$1.54-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-45.4%
The outlook
ProKidney Corp. currently reads as leaning bearish based on below its 50- & 200-day averages, 4% of the way from its 52-week low to high, avg target +306% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +306% vs current price
Analyst price target
~12-month · 6 analysts$6.25average target+305.8% vs now
Now $1.54
Low $1.00High $12.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$465.2M
52-wk high
$3.55
52-wk low
$1.45
50-day avg
$1.73
200-day avg
$2.11
Trailing P/E
—